This website uses technical, customisation and analytical cookies, both first-party and third-party, to anonymously facilitate browsing and analyse statistics on use of the website. Learn more
Search results
-
Comergent Technologies Inc.: Enterprise E-Commerce, Teaching Note
Rangan, V. Kasturi; Bellfor, MarieTeaching Note HBS-507087-EMarketingTeaching Note to (505-016). An abstract is not available for this product.Starting at €0.00
-
Akshaya Patra: Impact at Scale
Rangan, V. Kasturi; Appleby, SarahCase HBS-517028-EAkshaya Patra, an Indian NGO, had set an ambitious goal of serving 5 million free meals daily to India's schoolchildren. Founded in 2000, Akshaya Patra had thus far opened 25 high-capacity kitchens in 10 different States to provide a midday meal to nearly 1.65 million school children every day. With 110 million children in 1 million schools eligible for a mandatory midday meal, there was room to grow. Shridhar Venkat, its CEO, had to devise a pla...Starting at €8.20
-
Peabody Essex Museum: What Next
Rangan, V. Kasturi; Rayport, JeffreyCase HBS-520009-EMarketingDan Monroe, successful CEO of PEM, engineered a major transformation. Successor will either stay or change the course. The case describes the 25-year transformation of Peabody Essex Museum, which was created in 1993 by the merger of two sub-scale predecStarting at €8.20
-
How to Pay for Health Care
Porter, Michael E.; Kaplan, Robert S.Article HBS-R1607G-ELeadership and People ManagementThe United States stands at a crossroads in how to pay for health care. Fee for service, the dominant payment model in the U.S. and many other countries, is now widely recognized as perhaps the single biggest obstacle to improving health care delivery. A battle is currently raging, outside of the public eye, between the advocates of two radically different payment approaches: capitation and bundled payments. The stakes are high, and the outcome w...Starting at €8.20
-
How to Solve the Cost Crisis in Health Care
Kaplan, Robert S.; Porter, Michael E.Article HBS-R1109B-ELeadership and People ManagementU.S. health care costs currently exceed 17% of GDP and continue to rise. One fundamental reason that providers are unable to reverse the trend is that they don't understand what it costs to deliver patient care or how those costs compare with outcomes. To put it bluntly, few health care providers measure the actual costs for treating a given patient with a given medical condition over a full cycle of care, or compare the costs they incur with the...Starting at €8.20
-
How to Solve the Cost Crisis in Health Care (Spanish version)
Kaplan, Robert S.; Porter, Michael E.Article HBS-R1109BLeadership and People ManagementU.S. health care costs currently exceed 17% of GDP and continue to rise. One fundamental reason that providers are unable to reverse the trend is that they don't understand what it costs to deliver patient care or how those costs compare with outcomes. To put it bluntly, few health care providers measure the actual costs for treating a given patient with a given medical condition over a full cycle of care, or compare the costs they incur with the...Starting at €8.20
-
Gilead: Hepatitis-C Access Strategy (A)
Rangan, V. Kasturi; Rangan, Vikram; Bloom, David E.Case HBS-515025-EGilead had come up with an innovative drug for Hepatitis C, which affected 180 million people worldwide. The drug was priced at $1,000 a pill for the US market. Gilead had to decide how to price and market the pill in developing countries that bore the brunt of the disease. The company had earned accolades for its work in HIV/AIDS, where its innovative medicines now accounted for 60% of all patients on Anti-Retroviral (ARV) medicines. Much of thi...Starting at €8.20
-
Sanofi Pasteur: The Dengue Vaccine Dilemma
Rangan, V. Kasturi; Bloom, David E.; Dessain, Vincent; Billaud, EmilieCase HBS-514074-EIn 2012, Sanofi Pasteur was racing to develop a vaccine against dengue, a mosquito-borne disease, and was evaluating this product in a Phase IIb trial conducted with school children in Thailand. But while the candidate vaccine met the high safety expectations and a good balanced immune answer, it had a proof of efficacy of only 30%, far below the 70% mark the company had targeted. Guillaume Leroy, vice president of the Dengue Company at Sanofi Pa...Starting at €8.20
-
Medtronic: Navigating a Shifting Healthcare Landscape
Kaplan, Robert S.; Porter, Michael E.; Feeley, Thomas W; Hernandez, AleeCase HBS-718471-EStrategyMedtronic is adapting its strategy to changes in health care competition and payments. It has decided to develop new relationships with payers, hospitals, and physicians to become more accountable for patient outcomes and total costs. The case describes new forms of partnerships for therapy optimization, management of acute care episodes, and management of chronic care patients.Starting at €8.20
-
Los Nuevos Horizontes de Dell
Rangan, V. Kasturi; Bell, MarieCase HBS-503S30MarketingFundada en 1984, Dell Corp. ha logrado un crecimiento fenomenal, y para 2000 había superado los $ 25 mil millones en ventas y más de $ 2 mil millones en ingresos netos. En el cuarto trimestre de 2000, sin embargo, la tasa de crecimiento promedio de 30 años de la industria del PC se estrelló a un negativo del 10%. Dell debe tomar decisiones difíciles sobre cómo mantener su rentabilidad a la luz de su amplia cartera de productos - PC, estaciones de...Starting at €8.20